Intravenous UC-MSCs for Ischemic Stroke: What the MERIT Phase 1 Trial Tells Us
The MERIT phase 1 trial published in Cell Reports Medicine shows that intravenous UC-MSC therapy is safe in subacute ischemic stroke, with early NIHSS improvement signals. Here’s what clinicians need to know.
Read More »